Literature DB >> 7369106

Adriamycin cardiotoxicity.

I C Henderson, E Frei.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 7369106     DOI： 10.1016/0002-8703(80)90743-7

Source DB:  PubMed          Journal:  Am Heart J        ISSN： 0002-8703            Impact factor:   4.749


× No keyword cloud information.
  10 in total

1.  Hemodynamic effects of chronic 4'epi-adriamycin administration.

Authors:  J Milei; J J Ale; G Garay; F Otero; A Z Comba; H O Gugliotta; R A Storino
Journal:  Cardiovasc Drugs Ther       Date:  1990-12       Impact factor: 3.727

2.  The role of calcium in the toxicity of the myocardium.

Authors:  M Borgers
Journal:  Histochem J       Date:  1981-09

3.  Doxorubicin concentration time course in the myocardium after single administration to the dog. Possible role in the cardiac effects.

Authors:  Q Timour; P Nony; J Lang; M Lakhal; V Trillet; G Faucon
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

4.  Doxorubicin concentrations in plasma and myocardium and their respective roles in cardiotoxicity.

Authors:  Q Timour; P Nony; J Lang; M Lakhal; V Trillet; G Faucon
Journal:  Cardiovasc Drugs Ther       Date:  1988-01       Impact factor: 3.727

5.  [Possible prevention of adriamycin-induced cardiomyopathy by verapamil. Results of a pilot study].

Authors:  U Müllerleile; M Garbrecht; P Hanrath; B A Langenstein; K Bieber; W Bleifeld; D K Hossfeld
Journal:  Klin Wochenschr       Date:  1984-11-02

Review 6.  Doxorubicin (adriamycin) cardiomyopathy.

Authors:  E Saltiel; W McGuire
Journal:  West J Med       Date:  1983-09

7.  Selective sensory denervation by capsaicin aggravates adriamycin-induced cardiomyopathy in rats.

Authors:  Márta Katona; Krisztina Boros; Péter Sántha; Péter Ferdinandy; Mária Dux; Gábor Jancsó
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-11-10       Impact factor: 3.000

8.  Recombinant alpha 2 interferon is superior to doxorubicin for inoperable hepatocellular carcinoma: a prospective randomised trial.

Authors:  C L Lai; P C Wu; A S Lok; H J Lin; H Ngan; J Y Lau; H T Chung; M M Ng; E K Yeoh; M Arnold
Journal:  Br J Cancer       Date:  1989-12       Impact factor: 7.640

9.  An evaluation of hepatotoxicity in breast cancer patients receiving injection Doxorubicin.

Authors:  G Damodar; T Smitha; S Gopinath; S Vijayakumar; Ya Rao
Journal:  Ann Med Health Sci Res       Date:  2014-01

10.  Protective Effect of Boswellic Acids against Doxorubicin-Induced Hepatotoxicity: Impact on Nrf2/HO-1 Defense Pathway.

Authors:  Bassant M Barakat; Hebatalla I Ahmed; Hoda I Bahr; Alaaeldeen M Elbahaie
Journal:  Oxid Med Cell Longev       Date:  2018-02-06       Impact factor: 6.543
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.